Connor, Clark & Lunn Investment Management (CC&L)
KZR

Connor, Clark & Lunn Investment Management (CC&L)’s Kezar Life Sciences KZR Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,890
Closed -$278K – 1412
2023
Q1 		$278K Sell
8,890
-11,271
-56% -$652K ﹤0.01% 1020
2022
Q4 		$1.42M Sell
20,161
-7,107
-26% -$527K 0.01% 619
2022
Q3 		$2.35M Buy
27,268
+3,032
+13% +$295K 0.02% 466
2022
Q2 		$2M Buy
+24,236
New +$2.14M 0.01% 469

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s KZR Position: Q2 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Kezar Life Sciences (KZR) in Q2 2023, closing a stake of 8,890 shares — an estimated $278K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in KZR in Q2 2022 and held it in 4 quarters. The position peaked at $2.35M in Q3 2022. 104 funds tracked by Wall St. Rank hold KZR as of Q2 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Kezar Life Sciences position as of Q2 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 8,890 Kezar Life Sciences shares in Q2 2023, an estimated $278K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Kezar Life Sciences in Q2 2022 and held it in 4 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Kezar Life Sciences position peaked at $2.35M in Q3 2022.
  • 104 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2023, filed 10 Aug 2023.